Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bionxt Solutions Inc (BNXTF)

Bionxt Solutions Inc (BNXTF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 24,948
  • Shares Outstanding, K 113,402
  • Annual Sales, $ 280 K
  • Annual Income, $ -5,720 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.84
  • Price/Sales 101.24
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.01 on 11/29/24
  • Next Earnings Date 11/28/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1550 +41.94%
on 11/29/24
0.2464 -10.71%
on 12/19/24
+0.0519 (+30.87%)
since 11/20/24
3-Month
0.1431 +53.74%
on 09/23/24
0.2464 -10.71%
on 12/19/24
+0.0616 (+38.89%)
since 09/19/24
52-Week
0.1116 +97.13%
on 09/12/24
0.5656 -61.10%
on 01/08/24
-0.1266 (-36.53%)
since 12/20/23

Most Recent Stories

More News
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP

VANCOUVER, BC / ACCESSWIRE / December 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems,...

BNXT.CN : 0.3100 (+3.33%)
BNXTF : 0.2200 (-10.71%)
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment

VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems,...

BNXT.CN : 0.3100 (+3.33%)
BNXTF : 0.2200 (-10.71%)
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide

VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems,...

BNXT.CN : 0.3100 (+3.33%)
BNXTF : 0.2200 (-10.71%)
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

VANCOUVER, BC / ACCESSWIRE / November 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation product...

BNXT.CN : 0.3100 (+3.33%)
BNXTF : 0.2200 (-10.71%)
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

VANCOUVER, BC / ACCESSWIRE / October 29, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce that it has initiated the nationalization process...

BNXT.CN : 0.3100 (+3.33%)
BNXTF : 0.2200 (-10.71%)
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities

VANCOUVER, BC / ACCESSWIRE / September 26, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to provide an update on its flagship sublingual Cladribine...

BNXT.CN : 0.3100 (+3.33%)
BNXTF : 0.2200 (-10.71%)
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

BNXTF : 0.2200 (-10.71%)
BNXT.CN : 0.3100 (+3.33%)
XPHYF : 0.2836 (-31.13%)

Business Summary

BioNxt Solutions Inc. is a bioscience accelerator focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations. BioNxt Solutions Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 0.2200
2nd Resistance Point 0.2200
1st Resistance Point 0.2200
Last Price 0.2200
1st Support Level 0.2200
2nd Support Level 0.2200
3rd Support Level 0.2200

See More

52-Week High 0.5656
Fibonacci 61.8% 0.3922
Fibonacci 50% 0.3386
Fibonacci 38.2% 0.2850
Last Price 0.2200
52-Week Low 0.1116

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar